Stock Ratings / Health Care / REVB / forecast

ELAB (36) PPCB (36) BDRX (48) SILO (19) ⌘ Pro Terminal →

Revelation Biosciences Inc. (REVB) 12-Month Stock Forecast & Price Target Cone

$3.75 +0.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.75

Revelation Biosciences Inc. (REVB) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $2.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.75 (-0.04%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for REVB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (49/100 Composite)

🔍 WHY REVB SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (31% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 39.7 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (22% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$5.32-36.3% Next Q

Q2 (-2Q)

Grade C-$3.39+11.8% Next Q

Q3 (-1Q)

Grade C-$3.79-1.1% Next Q

Current

Grade D$3.75-5.4% Hist 90D α

Trajectory: C (57) → D (49)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a REVB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While REVB currently carries a cautious 49/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.77) and Max Pain ($3.94) forces dealer call-delta covering toward $42.63.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $REVB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “REVB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 49%NO 51%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your REVB Position Size: $10,000

Shares at $3.75: 2666.7 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.81

$7,493

$-2,507 (-25.1%)

12M Consensus BaseTarget $3.60

$9,600

$-400 (-4.0%)

12M Bull Case BreakoutTarget $42.63

$113,680

+$103,680 (+1036.8%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$4	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$40	69%	B
JP MorganUS Large-Cap Research	SELL	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring REVB)

✓Walkthrough of REVB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

REVB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.59%📐 HORIZONTAL RANGE

2026-10-30O $3.76H $4.03L $3.75C $3.75VOL 22.2K

RES: $10.19SUP: $2.63SMA50: $5.77SMA200: $8.16

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

REVB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 REVB Butterfly Map → + Track REVB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on REVB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for REVB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for REVB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (REVB)

Health Care Rank #372 of 1016 ⚔️ ELAB vs REVB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (REVB vs. ELAB, PPCB, BDRX, SILO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Revelation Biosciences Inc. (REVB) ranks #372 by composite RQD confidence (49/100, grade D) and #996 by equity capitalization ($2.1M). Within this direct 5-issuer industry benchmark cohort, REVB leads on earnings valuation at N/A trailing P/E, while REVB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. REVB currently leads its immediate peer cohort in composite quantitative strength at 49/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
REVB ACTIVE Revelation Biosciences Inc.	D	49/100	—	—	-35.0%	+0.81%	$2.1M	Benchmark Subject
ELAB PMGC Holdings Inc.	D-	36/100	—	31.4%	-35.0%	+2.72%	$2.1M	/elab-vs-revb →
PPCB Propanc Biopharma Inc.	D-	36/100	—	—	-35.0%	0.00%	$2.2M	/ppcb-vs-revb →
BDRX Biodexa Pharmaceuticals plc American Depositary Shs	D	48/100	—	—	—	-5.80%	$2.0M	/bdrx-vs-revb →
SILO Silo Pharma Inc.	E	19/100	—	38.6%	-35.0%	-6.72%	$2.4M	/silo-vs-revb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001810560

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Revelation Biosciences Inc. (REVB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.9M, operating cash flow of -$8.3M, and free cash flow of -$8.3M (+54.9% YoY). On the balance sheet, REVB closed FY2025 with $11.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$8.9M	-$8.3M	-$8.3M	$11.6M	—
FY2024 (FY)	2024-12-31	$0	-$15.0M	-$18.3M	-$18.3M	$6.6M	—
FY2023 (FY)	2023-12-31	$0	-$120.3K	-$7.3M	-$7.3M	—	—

3. REVB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is REVB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Revelation Biosciences Inc. (NASDAQ: REVB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $3.75 (+0.81% 1D, market cap $2.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, REVB ranks #372 in composite RQD confidence.

How does REVB compare to ELAB and PPCB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), REVB carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ELAB (PMGC Holdings Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M) and PPCB (Propanc Biopharma Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.2M). Among the 5-stock peer group, REVB leads on earnings multiple (N/A) while REVB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for REVB?

Per REVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001810560), Revelation Biosciences Inc. generated $0 in revenue, -$8.9M in net income, and -$8.3M in free cash flow against $11.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is REVB trading relative to its 50-day, 200-day, and 52-week technical levels?

REVB last traded at $3.75 (+0.81% on volume of 5,261 shares), positioning the stock -35.01% below its 50-day simple moving average ($5.77) and -54.04% below its 200-day simple moving average ($8.16). Across its 52-week range of $3.08 to $40.60, REVB sits at the 1.8% percentile with a 14-day RSI of 39.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.28 to $4.22).

REVB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is REVB's 12-month stock price target?

Revelation Biosciences Inc. (REVB) carries a 12-month consensus base price target of $3.6 (-4% from $3.75), with a bull-case target of $42.63 and a bear-case floor of $2.81.

Is REVB stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates REVB D (Sell — SELL) with an RQD Confidence score of 49/100.

Direct Sub-Reports: REVB RQD Cockpit REVB 12M Forecast REVB Earnings & Move REVB Dividends & DRIP REVB Insiders & 13F REVB Whale Options REVB Profit Sankey REVB News & Why